Immune Dysregulation and Current Targeted Biologics in Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a debilitating cutaneous disease characterized by a vicious cycle of chronic inflammation and tissue destruction that stems from disruption of the skin microbiome and abnormal activation of both the innate and adaptive immune system. A hallmark of HS pathophysiology...
Main Authors: | Rene Chen, Robyn Guo, Amy J. Petty, Tarannum Jaleel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Immuno |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-5601/4/1/4 |
Similar Items
-
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa
by: Elisa Molinelli, et al.
Published: (2023-05-01) -
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
by: Martora F, et al.
Published: (2024-01-01) -
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study
by: Federica Repetto, et al.
Published: (2023-04-01) -
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review
by: Angelo Ruggiero, et al.
Published: (2022-02-01) -
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
by: Fabrizio Martora, et al.
Published: (2023-04-01)